TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38498406

Group type: EXPERIMENTAL
Intervention: Combined regimen (transsphenoidal and transcranial approaches)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Non-combined regimen
Number of subjects: 647
Study: 38498512

Group type: EXPERIMENTAL
Intervention: Peer health coaching (PHC) intervention
Number of subjects: 0
Study: 38498587

Group type: EXPERIMENTAL
Intervention: ADAPT program plus standard medical care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical care alone (waitlist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADAPT program
Number of subjects: 0
Study: 38498623

Group type: EXPERIMENTAL
Intervention: Preoperative 11 C-methionine (MET) PET-MRI
Number of subjects: 10
Study: 38498781

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention comprising three to five individual self-management sessions, regular reporting of symptoms, and navigation to health care services.
Number of subjects: 503

Group type: COMPARATOR
Intervention: Regular outpatient visits with the physician (control group).
Number of subjects: 503
Study: 38498833

Group type: EXPERIMENTAL
Intervention: Digital patient education (PE) programme
Number of subjects: 180

Group type: COMPARATOR
Intervention: Face-to-face patient education (PE) programme
Number of subjects: 180
Study: 38498835

Group type: EXPERIMENTAL
Intervention: PPOS with oral micronized progesterone (200 mg from stimulation Day 1)
Number of subjects: 44
Study: 38498876

Group type: COMPARATOR
Intervention: CV gain-framing group
Number of subjects: 691820

Group type: COMPARATOR
Intervention: Repeated letter group
Number of subjects: 691820

Group type: EXPERIMENTAL
Intervention: Usual care group
Number of subjects: 691820
Study: 38498934

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) nucleic acid amplification testing
Number of subjects: 227

Group type: COMPARATOR
Intervention: Standard throat culture
Number of subjects: 227
Study: 38499015

Group type: EXPERIMENTAL
Intervention: Subcutaneous ND0612 (levodopa-carbidopa 60.0/7.5 mg/mL)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Oral levodopa-carbidopa
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Subcutaneous ND0612
Number of subjects: 381
Study: 38499238

Group type: EXPERIMENTAL
Intervention: NTM-PD progression (defined as initiation of treatment or clinician's intention to treat)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: NTM-PD progression rate
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Proportion of patients experiencing disease progression
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Risk factors for progression
Number of subjects: 477
Study: 38499287

Group type: EXPERIMENTAL
Intervention: Microburst VNS (μVNS)
Number of subjects: 33
Study: 38499320

Group type: EXPERIMENTAL
Intervention: FUNBALL programme
Number of subjects: 55
Study: 38499323

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation initiation within 1 hour of septic shock recognition
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bolus volume of 10-20 mL/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Exclusive administration of balanced crystalloids at 1 hour
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Exclusive administration of balanced crystalloids at 24 hours
Number of subjects: 63
Study: 38499358

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 82

Group type: COMPARATOR
Intervention: Oral acetaminophen
Number of subjects: 82
Study: 38499450

Group type: EXPERIMENTAL
Intervention: Fibre supplementation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 38499457

Group type: EXPERIMENTAL
Intervention: Pracinostat plus azacitidine (AZA)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo plus azacitidine (AZA)
Number of subjects: 406
Study: 38499501

Group type: EXPERIMENTAL
Intervention: Technical advances in ex vivo lung perfusion (EVLP) including repositioning donor lungs, perfusate adsorption/filtration, enrichment with plasma and nutrients, low-flow and pulsatile perfusion, positive outflow pressure, personalized ventilation strategies, and negative pressure ventilation.
Number of subjects: 0
Study: 38499753

Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2
Study: 38499943

Group type: EXPERIMENTAL
Intervention: EOI block with 40 ml 0.25% bupivacaine after anesthesia induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EOI block group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 38500051

Group type: EXPERIMENTAL
Intervention: Virtual pulmonary rehabilitation (PR) via video conference
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Virtual pulmonary rehabilitation (PR) via pre-recorded video
Number of subjects: 14
Study: 38500163

Group type: EXPERIMENTAL
Intervention: STRIPA intervention
Number of subjects: 160
Study: 38500166

Group type: EXPERIMENTAL
Intervention: Pharmacist integrated MOUD clinical model (PrIMO)
Number of subjects: 0
Study: 38500183

Group type: EXPERIMENTAL
Intervention: Audit and feedback (AF)-based intervention
Number of subjects: 5
Study: 38500184

Group type: EXPERIMENTAL
Intervention: EMONO consumers (339 patients)
Number of subjects: 993

Group type: EXPERIMENTAL
Intervention: EMONO consumers
Number of subjects: 993

Group type: EXPERIMENTAL
Intervention: Risk factors associated with SUD
Number of subjects: 993
Study: 38500190

Group type: EXPERIMENTAL
Intervention: Pharmacist-facilitated medication reviews with feedback on medication issues and recommendations to physicians.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation of a physician-pharmacist collaborative care intervention.
Number of subjects: 0
Study: 38500209

Group type: EXPERIMENTAL
Intervention: β-glucan-enriched oat bread
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 22
Study: 38500236

Group type: EXPERIMENTAL
Intervention: Clinical prediction tool for estimating 1-year mortality risk among hospitalized patients with dementia
Number of subjects: 235000

Group type: EXPERIMENTAL
Intervention: Validation cohort of clinical prediction tool
Number of subjects: 235000
Study: 38500292

Group type: EXPERIMENTAL
Intervention: Ponsegromab 100 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ponsegromab 200 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ponsegromab 400 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 38500476

Group type: EXPERIMENTAL
Intervention: Zandelisib 60 mg on Days 1-7 plus zanubrutinib 80 mg twice daily continuously in 28-day cycle
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Zandelisib plus zanubrutinib
Number of subjects: 70
Study: 38500494

Group type: EXPERIMENTAL
Intervention: Psychosocial deprivation and lower-quality caregiving
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: General psychopathology in early childhood
Number of subjects: 520

Group type: COMPARATOR
Intervention: Total symptom count
Number of subjects: 520
Study: 38500551

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) levels; specific intervention details not available.
Number of subjects: 0
Study: 38500576

Group type: EXPERIMENTAL
Intervention: BCG-Japan
Number of subjects: 17506

Group type: COMPARATOR
Intervention: BCG-Russia
Number of subjects: 17506
Study: 38500636

Group type: EXPERIMENTAL
Intervention: Gut microbiota profiles in men with prostate cancer
Number of subjects: 181

Group type: COMPARATOR
Intervention: Gut microbiota profiles in benign individuals
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Microbial functions related to gut microbiota
Number of subjects: 181
Study: 38500841

Group type: EXPERIMENTAL
Intervention: 10-day bismuth quadruple therapy
Number of subjects: 313

Group type: COMPARATOR
Intervention: 14-day bismuth quadruple therapy
Number of subjects: 313
Study: 38501082

Group type: EXPERIMENTAL
Intervention: Cultural Formulation Interview (CFI) administered in the intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 38501087

Group type: EXPERIMENTAL
Intervention: Adapted Internet-Delivered Cognitive Behaviour Therapy (ICBT) program
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-adapted Internet-Delivered Cognitive Behaviour Therapy (ICBT) program
Number of subjects: 41
Study: 38501187

Group type: EXPERIMENTAL
Intervention: Transradial access (TRA)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Transfemoral access (TFA)
Number of subjects: 772
Study: 38501214

Group type: EXPERIMENTAL
Intervention: Lower oxygenation group (Pao2 of 60 mm Hg)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Higher oxygenation group (Pao2 of 90 mm Hg)
Number of subjects: 726
Study: 38501219

Group type: EXPERIMENTAL
Intervention: Mivavotinib 80 mg once-daily plus nivolumab 3 mg/kg on days 1 and 15 in 28-day cycles
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mivavotinib 80 mg plus nivolumab 3 mg/kg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mivavotinib plus nivolumab
Number of subjects: 41
Study: 38501262

Group type: EXPERIMENTAL
Intervention: Niraparib maintenance treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38501300

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Number of subjects: 8162
Study: 38501508

Group type: EXPERIMENTAL
Intervention: Mixed Attention Model (MAM) - a hybrid care model incorporating a digital tool (mobile app) for self-management and asynchronous review by professionals.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Traditional face-to-face care model (control group).
Number of subjects: 360
Study: 38501690

Group type: EXPERIMENTAL
Intervention: Clinical trials for NUT carcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical trials for SMARCA4-DUT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical trials for SMARCB1-deficient neoplasms
Number of subjects: 0
Study: 38501751

Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ruxolitinib
Number of subjects: 0
Study: 38501895

Group type: EXPERIMENTAL
Intervention: levcromakalim
Number of subjects: 27

Group type: COMPARATOR
Intervention: saline
Number of subjects: 27
Study: 38501946

Group type: EXPERIMENTAL
Intervention: Methylene blue photodynamic therapy (MB-PDT) performed after percutaneous abscess drainage with laser illumination at a fluence rate of 20 mW/cm.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care abscess management including image-guided percutaneous drainage and antibiotics.
Number of subjects: 0
Study: 38501980

Group type: EXPERIMENTAL
Intervention: Esketamine combined with pregabalin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline and placebo capsules (Control)
Number of subjects: 90
Study: 38501987

Group type: EXPERIMENTAL
Intervention: Capsaicin-induced shoulder pain
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kinesiophobia scores
Number of subjects: 30
Study: 38501989

Group type: EXPERIMENTAL
Intervention: NLP-based approach
Number of subjects: 10314

Group type: COMPARATOR
Intervention: Human retrieval
Number of subjects: 10314
Study: 38502056

Group type: EXPERIMENTAL
Intervention: Mirabegron (200 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bisoprolol (dose not specified)
Number of subjects: 8
Study: 38502074

Group type: EXPERIMENTAL
Intervention: Aspirin, 81 mg once daily for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo, identical pills once daily for 6 months
Number of subjects: 80
Study: 38502127

Group type: EXPERIMENTAL
Intervention: Usual care plus a web-based decision aid (MyDecision/MiDecisión)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study: 38502126

Group type: EXPERIMENTAL
Intervention: S100B biomonitoring group
Number of subjects: 2078

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2078
Study: 38502156

Group type: EXPERIMENTAL
Intervention: PLANTS intervention (web-based training for school staff)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active comparator group (publicly available sexual and gender minority youths resources or training)
Number of subjects: 0
Study: 38502173

Group type: EXPERIMENTAL
Intervention: Social Media-Delivered Melanoma Prevention Program (intervention group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Attention-matched control condition (control group)
Number of subjects: 25
Study: 38502193

Group type: EXPERIMENTAL
Intervention: Rapamycin-regulated DARIC33 T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapamycin withdrawal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DARIC33 T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: DARIC33
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapamycin dosing schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase I DARIC33 trial (PLAT-08, NCT05105152)
Number of subjects: 0
Study: 38502195

Group type: EXPERIMENTAL
Intervention: FF-10101 (oral), doses ranging from 10 to 225 mg per day and 50 to 100 mg twice daily (BID)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: FF-10101 (oral), recommended phase 2 dose was 75 mg BID
Number of subjects: 54
Study: 38502198

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 1550
Study: 38502268

Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation (FCV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 10
Study: 38502425

Group type: EXPERIMENTAL
Intervention: Lacosamide 50 mg Bid for three months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 200
Study: 38502516

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRVB) mobile app
Number of subjects: 28
Study: 38502656

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV+gp120/MF59
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV+gp120/alum
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV+gp120/MF59 coadministration
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV+gp120/no adjuvant
Number of subjects: 132
Study: 38502672

Group type: EXPERIMENTAL
Intervention: In-home body weight support harness system (BWSS)
Number of subjects: 32
Study: 38502709

Group type: EXPERIMENTAL
Intervention: Rezafungin (Rezzayo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator echinocandin
Number of subjects: 0
Study: 38502720

Group type: EXPERIMENTAL
Intervention: Complete revascularization based on residual Jeopardy Score (rJS) 0
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Complete revascularization based on residual Jeopardy Score (rJS) 2
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Incomplete revascularization based on residual Jeopardy Score (rJS) ≥4
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Post-PCI untreated high-grade lesions in the LCX
Number of subjects: 903
Study: 38502819

Group type: EXPERIMENTAL
Intervention: Combination Lavender/Peppermint Aromatherapy Patch
Number of subjects: 0
Study: 38502892

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 846

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 846

Group type: COMPARATOR
Intervention: Comparison of Tenecteplase vs Alteplase
Number of subjects: 846
Study: 38502995

Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd)
Number of subjects: 0
Study: 38503247

Group type: EXPERIMENTAL
Intervention: Interactive learning method
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional lecture-style teaching
Number of subjects: 134
Study: 38503386

Group type: EXPERIMENTAL
Intervention: Controlled hypothermic preservation
Number of subjects: 1061
Study: 38503417

Group type: EXPERIMENTAL
Intervention: WT1/DC-vaccine immunotherapy combined with conventional antiglioma treatment (chemoradiation with oral temozolomide 90 mg/m2)
Number of subjects: 10
Study: 38503415

Group type: EXPERIMENTAL
Intervention: Weekly injections of semaglutide for 30 weeks
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 38503423

Group type: EXPERIMENTAL
Intervention: Bootle Boot Camp (BBCamp) with movement tracking feedback
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bootle Boot Camp (BBCamp) without movement tracking feedback
Number of subjects: 16
Study: 38503477

Group type: EXPERIMENTAL
Intervention: DDM lens
Number of subjects: 168

Group type: COMPARATOR
Intervention: SV lens
Number of subjects: 168
Study: 38503755

Group type: EXPERIMENTAL
Intervention: Exemestane plus everolimus and palbociclib (100 mg palbociclib, 5 mg everolimus, 25 mg exemestane)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exemestane plus everolimus and palbociclib
Number of subjects: 32
Study: 38503870

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral self-help intervention with human guidance (GU)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral self-help intervention with automated messages (AM)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral self-help intervention (GU and AM combined)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Waitlist control group (WL)
Number of subjects: 243
Study: 38503990

Group type: EXPERIMENTAL
Intervention: Fitbit physical activity tracker with feedback on step count
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63
Study: 38504015

Group type: EXPERIMENTAL
Intervention: Nivolumab (Arm A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nivolumab-relatlimab (Arm B)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall (both arms)
Number of subjects: 32
Study: 38504036

Group type: EXPERIMENTAL
Intervention: QoR-15 at H24
Number of subjects: 375
Study: 38504157

Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioral therapy (iCBT)
Number of subjects: 109

Group type: COMPARATOR
Intervention: psychoeducation
Number of subjects: 109
Study: 38504166

Group type: EXPERIMENTAL
Intervention: Preoperative frailty assessment in geriatric patients undergoing noncardiac surgery
Number of subjects: 856
Study: 38504173

Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV), administered in two doses two months apart.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age-/gender-matched HIV-uninfected controls
Number of subjects: 0
Study: 38504186

Group type: EXPERIMENTAL
Intervention: Single vessel disease (Group A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Multiple vessel disease (Group B)
Number of subjects: 89
Study: 38504215

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation with palliative care education (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional pulmonary rehabilitation (control group)
Number of subjects: 0
Study: 38504243

Group type: EXPERIMENTAL
Intervention: Formocresol pulpotomy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Zinc-oxide and eugenol pulpectomy
Number of subjects: 39
Study: 38504260

Group type: EXPERIMENTAL
Intervention: Plasma chlordecone concentrations (highest vs. lowest tertile)
Number of subjects: 182
Study: 38504343

Group type: EXPERIMENTAL
Intervention: m-Health-assisted lifestyle intervention program consisting of health education, dietary guidance, and physical activity reinforcement for one academic year.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Usual practice group (control group).
Number of subjects: 6
Study: 38504367

Group type: EXPERIMENTAL
Intervention: HEPA filtration units (24-week home intervention)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control units (without HEPA and carbon filters)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: HEPA filtration units
Number of subjects: 228
Study: 38504422

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study: 38504437

Group type: EXPERIMENTAL
Intervention: AZD8233 (antisense oligonucleotide targeting PCSK9)
Number of subjects: 219
Study: 38505288

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid (UDCA)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Non-Ursodeoxycholic Acid (non-UDCA)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Patients transplanted between 3 and 6 months ago
Number of subjects: 91
Study: 38505303

Group type: EXPERIMENTAL
Intervention: AF with CAD
Number of subjects: 2020

Group type: COMPARATOR
Intervention: AF without CAD
Number of subjects: 2020
Study: 38505522

Group type: EXPERIMENTAL
Intervention: Abaloparatide 80 μg
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 38505729

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 12151

Group type: COMPARATOR
Intervention: Placebo or usual care
Number of subjects: 12151
Study: 38505928

Group type: EXPERIMENTAL
Intervention: FA-acetaminophen 1000 mg
Number of subjects: 664

Group type: COMPARATOR
Intervention: ES-acetaminophen 1000 mg
Number of subjects: 664

Group type: COMPARATOR
Intervention: LG-ibuprofen 400 mg
Number of subjects: 664

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study: 38506171

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 272
Study: 38506343

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 17282
Study: 38506710

Group type: EXPERIMENTAL
Intervention: NOUS-PEV (vector-based personalized vaccine)
Number of subjects: 6
Study: 38506889

Group type: EXPERIMENTAL
Intervention: MOABP with an oral regimen of neomycin and metronidazole (n=277)
Number of subjects: 565

Group type: COMPARATOR
Intervention: MBP plus placebo (n=288)
Number of subjects: 565
Study: 38506892

Group type: EXPERIMENTAL
Intervention: Fido chatbot (n=36)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Self-help book (control group, n=38)
Number of subjects: 81
Study: 38506900

Group type: EXPERIMENTAL
Intervention: Cytotoxic treatments (chemo- and radiotherapy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fertility preservation treatments (freezing of gametes and gonadal tissue)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Follow-up assessments
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fertility-preserving procedures
Number of subjects: 50
Study: 38506903

Group type: EXPERIMENTAL
Intervention: Higher SM group (29/50, 58%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lower SM group (21/50, 42%)
Number of subjects: 50